» Articles » PMID: 33855267

Factors Associated with Poor Quality of Life in a Canadian Cohort of Patients with Inflammatory Bowel Disease: A Cross-sectional Study

Overview
Specialty Gastroenterology
Date 2021 Apr 15
PMID 33855267
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Health-related quality of life (QoL) is often adversely affected in patients with inflammatory bowel disease (IBD). We aimed to identify factors associated with poor QoL among Canadian patients with IBD in clinical remission.

Methods: We enrolled patients at a single academic tertiary care center with inactive IBD. All eligible patients completed a series of questionnaires that included questions on demographics, disease activity, anxiety, depression and the presence of irritable bowel syndrome (IBS) symptoms. Stool sample for fecal calprotectin (FC) was also collected to assess for subclinical inflammation. The primary outcome measure was QoL assessed by the short inflammatory bowel disease questionnaire (SIBDQ), with planned subgroup comparisons for fatigue, anxiety, depression and IBS symptoms.

Results: Ninety-three patients were eligible for inclusion in this study. The median SIBDQ scores were lower in patients with anxiety ( < 0.001), depression ( = 0.004), IBS symptoms ( < 0.001) and fatigue ( = 0.018). Elevated FC in patients in clinical remission did not impact QoL. These findings were consistent on multivariate linear regression.

Conclusions: Anxiety, depression, fatigue and IBS symptoms are all independently associated with lower QoL in patients with inactive IBD. Clinicians are encouraged to screen for these important factors as they may detrimentally impact QoL in IBD patients even in clinical remission.

Citing Articles

Depression and active disease are the major risk factors for fatigue and sleep disturbance in inflammatory bowel disease with consequent poor quality of life: Analysis of the interplay between psychosocial factors from the developing world.

Pal P, Banerjee R, Vijayalaxmi P, Reddy D, Tandan M Indian J Gastroenterol. 2023; 43(1):226-236.

PMID: 37851205 DOI: 10.1007/s12664-023-01462-5.


Fatigue Is Associated with Anxiety and Lower Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Remission.

Stroie T, Preda C, Meianu C, Istratescu D, Manuc M, Croitoru A Medicina (Kaunas). 2023; 59(3).

PMID: 36984533 PMC: 10058711. DOI: 10.3390/medicina59030532.


Healthcare Needs and Perceptions of People Living With Inflammatory Bowel Disease in Australia: A Mixed-Methods Study.

Prasad S, Walker M, Talley N, Keely S, Kairuz T, Jones M Crohns Colitis 360. 2023; 4(1):otab084.

PMID: 36777548 PMC: 9802190. DOI: 10.1093/crocol/otab084.


Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment.

Calvino-Suarez C, Ferreiro-Iglesias R, Baston-Rey I, Barreiro-de Acosta M Int J Environ Res Public Health. 2021; 18(13).

PMID: 34281095 PMC: 8296948. DOI: 10.3390/ijerph18137159.

References
1.
Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

2.
Jones J, Nguyen G, Benchimol E, Bernstein C, Bitton A, Kaplan G . The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life. J Can Assoc Gastroenterol. 2019; 2(Suppl 1):S42-S48. PMC: 6512247. DOI: 10.1093/jcag/gwy048. View

3.
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010; 4(1):7-27. DOI: 10.1016/j.crohns.2009.12.003. View

4.
Krass I, Schieback P, Dhippayom T . Adherence to diabetes medication: a systematic review. Diabet Med. 2014; 32(6):725-37. DOI: 10.1111/dme.12651. View

5.
Knowles S, Graff L, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A . Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I. Inflamm Bowel Dis. 2018; 24(4):742-751. DOI: 10.1093/ibd/izx100. View